Time to Hit HIV, Early and Hard

doi:10.1056/NEJM199508173330710

Volume 333:450-451		August 17, 1995		Number 7

Time to Hit HIV, Early and Hard

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

Full Text

Purchase this article

Add to Personal Archive

Add to Citation Manager

Notify a Friend

E-mail When Cited

PubMed Citation

Early treatment of asymptomatic human immunodeficiency virustype 1 (HIV-1) infection remains controversial. In the AIDSClinical Trials Group 019 study, zidovudine was shown in 1990to slow the clinical progression to AIDS in infected but asymptomaticsubjects.¹ However, a follow-up of those subjects found no evidenceof longer survival with the use of zidovudine.² Furthermore,the Concorde study found that there was not only no survivalbenefit from early treatment with zidovudine, but also no effecton the overall progression of disease.³ Now, in this issue ofthe Journal, Volberding et al. report the further results ofthe AIDS . . . [Full Text of this Article]

References

This article has been cited by other articles:

Jimenez-Nacher, I., Garcia, B., Barreiro, P., Rodriguez-Novoa, S., Morello, J., Gonzalez-Lahoz, J., de Mendoza, C., Soriano, V. (2008). Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements. J Antimicrob Chemother 62: 816-822 [Abstract] [Full Text]
Braithwaite, R. S., Roberts, M. S., Chang, C. C. H., Goetz, M. B., Gibert, C. L., Rodriguez-Barradas, M. C., Shechter, S., Schaefer, A., Nucifora, K., Koppenhaver, R., Justice, A. C. (2008). Influence of Alternative Thresholds for Initiating HIV Treatment on Quality-Adjusted Life Expectancy: A Decision Model. ANN INTERN MED 148: 178-185 [Abstract] [Full Text]
Shechter, S. M., Bailey, M. D., Schaefer, A. J., Roberts, M. S. (2008). The Optimal Time to Initiate HIV Therapy Under Ordered Health States. Operations Research 56: 20-33 [Abstract]
VandeWoude, S., Apetrei, C. (2006). Going Wild: Lessons from Naturally Occurring T-Lymphotropic Lentiviruses. Clin. Microbiol. Rev. 19: 728-762 [Abstract] [Full Text]
Mounier, N., Spina, M., Gabarre, J., Raphael, M., Rizzardini, G., Golfier, J.-B., Vaccher, E., Carbone, A., Coiffier, B., Chichino, G., Bosly, A., Tirelli, U., Gisselbrecht, C., for the French-Italian cooperative group, (2006). AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. Blood 107: 3832-3840 [Abstract] [Full Text]
Flint, S.R., Tappuni, A., Leigh, J., Schmidt-Westhausen, A.-M., MacPhail, L. (2006). (B3) Markers of Immunodeficiency and Mechanisms of HAART Therapy on Oral Lesions. Adv. Dent. Res. 19: 146-151 [Abstract] [Full Text]
Newman, C., Persson, A., Ellard, J. (2006). 'We just don't know': ambivalence about treatment strategies in the Australian community-based HIV media.. Health (London) 10: 191-210 [Abstract]
Persson, A. (2004). Incorporating Pharmakon: HIV, Medicine, and Body Shape Change. Body Society 10: 45-67 [Abstract]
Deeks, S. G., Kitchen, C. M. R., Liu, L., Guo, H., Gascon, R., Narvaez, A. B., Hunt, P., Martin, J. N., Kahn, J. O., Levy, J., McGrath, M. S., Hecht, F. M. (2004). Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood 104: 942-947 [Abstract] [Full Text]
Rosengarten, M. (2004). The Challenge of HIV for Feminist Theory. Feminist Theory 5: 205-222 [Abstract]
Waters, L., Stebbing, J., Jones, R., Michailidis, C., Sawleshwarkar, S., Mandalia, S., Bower, M., Nelson, M., Gazzard, B. (2004). A comparison of the CD4 response to antiretroviral regimens in patients commencing therapy with low CD4 counts. J Antimicrob Chemother 54: 503-507 [Abstract] [Full Text]
Stebbing, J., Gazzard, B., Douek, D. C. (2004). Where Does HIV Live?. NEJM 350: 1872-1880 [Full Text]
Sparano, J. A., Lee, S., Chen, M. G., Nazeer, T., Einzig, A., Ambinder, R. F., Henry, D. H., Manalo, J., Li, T., Von Roenn, J. H. (2004). Phase II Trial of Infusional Cyclophosphamide, Doxorubicin, and Etoposide in Patients With HIV-Associated Non-Hodgkin's Lymphoma: An Eastern Cooperative Oncology Group Trial (E1494). JCO 22: 1491-1500 [Abstract] [Full Text]
Gonzalez-Lopez, C., Arias, A., Pariente, N., Gomez-Mariano, G., Domingo, E. (2004). Preextinction Viral RNA Can Interfere with Infectivity. J. Virol. 78: 3319-3324 [Abstract] [Full Text]
Kinloch-de Loes, S. (2004). Role of therapeutic vaccines in the control of HIV-1. J Antimicrob Chemother 53: 562-566 [Abstract] [Full Text]
Alter, G., Hatzakis, G., Tsoukas, C. M., Pelley, K., Rouleau, D., LeBlanc, R., Baril, J.-G., Dion, H., Lefebvre, E., Thomas, R., Cote, P., Lapointe, N., Routy, J.-P., Sekaly, R.-P., Conway, B., Bernard, N. F. (2003). Longitudinal Assessment of Changes in HIV-Specific Effector Activity in HIV-Infected Patients Starting Highly Active Antiretroviral Therapy in Primary Infection. J. Immunol. 171: 477-488 [Abstract] [Full Text]
Ahdieh-Grant, L., Yamashita, T. E., Phair, J. P., Detels, R., Wolinsky, S. M., Margolick, J. B., Rinaldo, C. R., Jacobson, L. P. (2003). When to Initiate Highly Active Antiretroviral Therapy: A Cohort Approach. Am J Epidemiol 157: 738-746 [Abstract] [Full Text]
King, J. T. Jr., Justice, A. C., Roberts, M. S., Chang, C.-C. H., Fusco, J. S. (2003). Long-Term HIV/AIDS Survival Estimation in the Highly Active Antiretroviral Therapy Era. Med Decis Making 23: 9-20 [Abstract]
Anastos, K., Barron, Y., Miotti, P., Weiser, B., Young, M., Hessol, N., Greenblatt, R. M., Cohen, M., Augenbraun, M., Levine, A., Munoz, A., for the Women's Interagency HIV Study Collaborativ, (2002). Risk of Progression to AIDS and Death in Women Infected With HIV-1 Initiating Highly Active Antiretroviral Treatment at Different Stages of Disease. Arch Intern Med 162: 1973-1980 [Abstract] [Full Text]
Hogan, C. M., Hammer, S. M. (2001). Host Determinants in HIV Infection and Disease: Part 2: Genetic Factors and Implications for Antiretroviral Therapeutics. ANN INTERN MED 134: 978-996 [Abstract] [Full Text]
Ahdieh, L., Gange, S. J., Greenblatt, R., Minkoff, H., Anastos, K., Young, M., Nowicki, M., Kovacs, A., Cohen, M., Munoz, A. (2000). Selection by Indication of Potent Antiretroviral Therapy Use in a Large Cohort of Women Infected with Human Immunodeficiency Virus. Am J Epidemiol 152: 923-933 [Abstract] [Full Text]
Oxenius, A., Price, D. A., Easterbrook, P. J., O'Callaghan, C. A., Kelleher, A. D., Whelan, J. A., Sontag, G., Sewell, A. K., Phillips, R. E. (2000). Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc. Natl. Acad. Sci. USA 97: 3382-3387 [Abstract] [Full Text]
Henry, K. (2000). The Case for More Cautious, Patient-Focused Antiretroviral Therapy. ANN INTERN MED 132: 306-311 [Abstract] [Full Text]
Kashuba, A. D. M., Dyer, J. R., Kramer, L. M., Raasch, R. H., Eron, J. J., Cohen, M. S. (1999). Antiretroviral-Drug Concentrations in Semen: Implications for Sexual Transmission of Human Immunodeficiency Virus Type 1. Antimicrob. Agents Chemother. 43: 1817-1826 [Full Text]
D'Cruz, O. J., Shih, M.-J., Yiv, S. H., Chen, C.-L., Uckun, F. M. (1999). Synthesis, characterization and preclinical formulation of a dual-action phenyl phosphate derivative of bromo-methoxy zidovudine (compound WHI-07) with potent anti-HIV and spermicidal activities. Mol Hum Reprod 5: 421-432 [Abstract] [Full Text]
Henderson, D. K. (1999). Postexposure Chemoprophylaxis for Occupational Exposures to the Human Immunodeficiency Virus. JAMA 281: 931-936 [Full Text]
Justice, A. C., Weissman, S. (1998). The Survival Experience of Older and Younger Adults with AIDS: Is there a Growing Gap in Survival?. Research on Aging 20: 665-685 [Abstract]
Janssen, R. S., Satten, G. A., Stramer, S. L., Rawal, B. D., O'Brien, T. R., Weiblen, B. J., Hecht, F. M., Jack, N., Cleghorn, F. R., Kahn, J. O., Chesney, M. A., Busch, M. P. (1998). New Testing Strategy to Detect Early HIV-1 Infection for Use in Incidence Estimates and for Clinical and Prevention Purposes. JAMA 280: 42-48 [Abstract] [Full Text]
Walker, B. D., Basgoz, N. (1998). Treat HIV-1 Infection Like Other Infections--Treat It. JAMA 280: 91-93 [Full Text]
Samet, J. H., Freedberg, K. A., Stein, M. D., Lewis, R., Savetsky, J., Sullivan, L., Levenson, S. M., Hingson, R. (1998). Trillion Virion Delay: Time From Testing Positive for HIV to Presentation for Primary Care. Arch Intern Med 158: 734-740 [Abstract] [Full Text]
Saravolatz, L. D., Winslow, D. L., Collins, G., Hodges, J. S., Pettinelli, C., Stein, D. S., Markowitz, N., Reves, R., Loveless, M. O., Crane, L., Thompson, M., Abrams, D., Investigators for the Terry Beirn Community Progra, (1996). Zidovudine Alone or in Combination with Didanosine or Zalcitabine in HIV-Infected Patients with the Acquired Immunodeficiency Syndrome or Fewer Than 200 CD4 Cells per Cubic Millimeter. NEJM 335: 1099-1106 [Abstract] [Full Text]
Corey, L., Holmes, K. K. (1996). Therapy for Human Immunodeficiency Virus Infection -- What Have We Learned?. NEJM 335: 1142-1144 [Full Text]
Phillips, A. N, Smith, G. D., Johnson, M. A (1996). For Debate: Will we ever know when to treat HIV infection?. BMJ 313: 608-610 [Full Text]
Jolles, S., De Loes, S. K., Johnson, M. A, Janossy, G. (1996). Primary HIV-1 infection: a new medical emergency?. BMJ 312: 1243-1244 [Full Text]
Price, R.W. (1996). AIDS Dementia Complex: A Complex, Slow Virus "Model" of Acquired Genetic Neurodegenerative Disease. Cold Spring Harb Symp Quant Biol 61: 759-770 [Abstract]
Fessel, W. J., Schwartz, D. H., Cates, W., Cohen, M. S., Kinloch-de Loes, S., Perrin, L., Hirschel, B., Ho, D. D. (1995). Early Treatment of HIV Infection. NEJM 333: 1782-1783 [Full Text]
(1995). Does It Help to Give AZT during Primary HIV Infection?. AIDS Clin Care 1995: 4-4 [Full Text]
(1995). ....BUT ENCOURAGING RESULTS IN ANOTHER. JWatch General 1995: 4-4 [Full Text]

Comments and questions? Please contact us.